Targeting UCH-L1 may increase and maintain ERα level by promoting the degradation of EGFR, thereby sensitizing ERα (-) breast cancer cells to the selective ER modulator such as tamoxifen (Figure 7H). Here, ESR1 is linked to breast carcinoma.